Navigation Links
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Date:7/9/2009

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R788 (fostamatinib disodium) produced significant clinical improvement in rheumatoid arthritis (RA) patients in the recently completed TASKi2 Phase 2b clinical trial of 457 patients treated for up to 6 months. The groups treated with 100 mg of R788 bid (twice a day) and 150 mg qd (once a day) reported higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group. The efficacy results for the two dosing groups were comparable, although the response rates for the 100 mg bid group was uniformly greater. Consistent with the previous Phase 2a clinical trial (TASKi1), the onset of effect of R788 occurred within one week after the initiation of therapy and was maintained. The most frequent adverse events were expected based on TASKi1 and appear to be manageable. The significant, early and sustained efficacy, combined with a good safety profile, supports Rigel's plans to conduct corporate partnership discussions with respect to R788 and initiate a Phase 3 clinical program with R788 in RA in the first half of 2010 with a corporate partner.

Rigel will host a conference call today at 8:00am EDT/5:00am PDT to discuss these results (see conference call details below).

"These are impressive results," said James M. Gower, chairman and chief executive officer of Rigel. "The data from this clinical trial and the soon to be completed TASKi3 clinical trial, a total of over 670 patients, will guide the design of the Phase 3 trials that we plan to launch with a corporate partner in the first half of next year, " he added.


    Efficacy Results

    Treatment    N of Pts   ACR 20     ACR 50    ACR 70    DAS28<2.6

    Placebo        153      53 (35%)   29 (19%)  16 (10%)  9 (
'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015  Novartis Pharmaceuticals Corporation (NPC) has been named the ... row on the annual DiversityInc Top 50 Companies for Diversity ... Companies for Diversity on April 23 at an awards ceremony ... ranked second on the DiversityInc Top 10 Companies for Recruitment ... Resource Groups list. David Epstein , ...
(Date:4/24/2015)... , April 24, 2015 Hospira, Inc. ... the development of biosimilar therapies, spoke about the importance ... the European Generics Association (EGA) annual European Biosimilars Group ... The company also announced the publication of a pivotal ... achieving the full promise of biosimilars." ...
(Date:4/23/2015)... (NYSE: RMD ) today announced results for its ... was $422.5 million, a 6 percent increase compared to ... increase on a constant currency basis).  Net income was ... the quarter ended March 31, 2014.  Diluted earnings per ... 2 percent compared to the quarter ended March 31, ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
... Dec. 20, 2010 Ambit Biosciences (Ambit), ... trials for two products AC430, a selective Janus Kinase ... The Phase I trial for AC430 is a ... trial in healthy volunteers.  AC430 will be administered orally ...
... Center for Business Intelligence (CBI) has been recognized as a ... was awarded recently to Kathleen Y. Coffey, CBI President, by ... Boston Park Plaza Hotel.   The Top ... $47.5B in annual revenue and $202,664 employees. Over 500 women ...
Cached Medicine Technology:Ambit Biosciences Initiates Two Phase I Clinical Trials 2The Center for Business Intelligence (CBI) Receives Top 100 Women-Led Businesses Award 2
(Date:4/24/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... auto insurance for senior citizens . , Senior ... does not mean that they cannot find affordable coverage. ... can find the right coverage for their cars at ... like http://lowcostcarinsuranceprice.com/ provides free leads from various ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two ... and cognition. , A unique combination of herbs ... Wellness Flavonoid Complex apart from other antioxidant supplements. ... to support antioxidation versus the use of single ... tea extract, Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 ...
(Date:4/24/2015)... With years of experience providing ... proud to be partnered with a veterinary college where ... year. This partnership has brought new payment options for ... After providing an in-house payment plan for many years, ... wanted to increase financing options available to avoid having ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 IntelliSoft ... provider enrollment and contract management software, featured IntelliCred ... Medical Staff Services Annual Educational Conference (IAMSS) ... Resort in Oak Brook, Illinois. , Notable improvements ... , Contract Linking: A ...
(Date:4/24/2015)... Telematics Berlin is the foremost Automotive Data event ... suppliers, content providers, associations and government bodies. From industry ... see them converge in Berlin. This year’s start-up competition ... companies currently at the forefront of Europe’s Silicon Valley ... centric products, ParkTAG are one of the first social ...
Breaking Medicine News(10 mins):Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:IntelliSoft Group Version 14.2 of IntelliCred featured at the Illinois Association of Medical Staff Services Annual Educational Conference 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3
... American Heart Association extend their sympathy to the family and friends ... , "It,s a shame when someone his age dies so ... "Although we don,t know all the details of the situation, ... react quickly. Our thoughts and prayers are with the Jackson ...
... Wash., June 25 Verathon Inc., maker of ... announced today the appointment of Kendall Stever as ... will include management and oversight of the Company,s ... functions for company headquarters in Washington State, taxation, ...
... finds , THURSDAY, June 25 (HealthDay News) -- Consumption of ... associated with it. Worldwide, one in 25 deaths and 5 ... are related to alcohol, according to a new study. , ... of about 1.6 gallons (6.2 liters) of pure ethanol a ...
... ... Cases, , ... CO (PRWEB) June 25, 2009 -- Two grocery checkers--a 28-year-old female triathlete and a ... are identical. Which employee will return to work sooner? Is there anything you can ...
... In a 6-5 decision in Richmond Medical Center v. ... ban on partial birth infanticide -- a law that mirrors the ... United for Life (AUL) provided litigation support to the ... Virginia,s law. In addition, AUL Senior Counsel Clarke Forsythe assisted ...
... there is no cure for HIV/AIDS. However, major advances ... with HIV/AIDS. For example, Dr. Michael Hall has revolutionized ... diseases. He envisions a synergy between the evolution of ... the Hall Longevity Clinic Lifecard , ...
Cached Medicine News:Health News:American Heart Association Extends Sympathy to Family of Singer Michael Jackson 2Health News:Verathon Inc. Appoints Kendall Stever as Chief Financial Officer 2Health News:Alcohol-Related Ills Increasing Worldwide 2Health News:Alcohol-Related Ills Increasing Worldwide 3Health News:MDGuidelines Offers New Predictive Modeling Feature 2Health News:MDGuidelines Offers New Predictive Modeling Feature 3Health News:MDGuidelines Offers New Predictive Modeling Feature 4Health News:Americans United for Life Applauds Fourth Circuit Protecting Women and Children by Upholding Virginia Partial Birth Abortion Statute 2Health News:Dr. Hall Revolutionizes National HIV Testing Day 2
... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent ... and quantitative determination of IgG antibody to ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
... Inc. Mumps IgG ELISA test system is ... IgG antibody in human serum. When performed ... this test, together with other clinical information, ... status, and/or aid in the diagnosis of ...
... Mumps IgM Enzyme-Linked Immunosorbent Assay ... qualitative detection of IgM antibody ... for the determination of immunological ... this kit have not been ...
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
Medicine Products: